News & Updates

The IL-13 inhibitor cendakimab appears to be beneficial in the treatment of atopic dermatitis (AD), with the results of a phase II study showing that a dosing schedule of 720 mg once weekly helps reduce the severity of the said condition.

Benralizumab offers more sustained and earlier elimination of oral GCs vs mepolizumab in patients with relapsing or refractory EGPA, suggests a post hoc analysis of the MANDARA study presented at EULAR 2024

The use of Janus kinase (JAK) inhibitors in the treatment of major autoimmune diseases appears to reduce the risk of age-related macular degeneration (AMD) for people above 40 years of age, according to a study.

Nearly half of patients with classic dermatomyositis (DM) develop into postmyopathic (PM)DM, according to a study. Many of them continue to suffer from muscle disease or have moderate or severe skin disease.

New drug applications approved by US FDA as of 16-30 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Among patients with psoriasis, those who smoke or did previously, have been exposed to biologics, at older age, or with higher BMI appear to have poorer response to treatment with biologics, as reported in a meta-analysis.

A recent study recommends the real-life practice of reflectance confocal microscopy (RCM) to allow less invasive diagnostic procedures for patients.